GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » EBITDA Margin %
Switch to:

Biogen (BUE:BIIB) EBITDA Margin %

: 24.89% (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biogen's EBITDA for the three months ended in Mar. 2023 was ARS121,118 Mil. Biogen's Revenue for the three months ended in Mar. 2023 was ARS486,566 Mil. Therefore, Biogen's EBITDA margin for the quarter that ended in Mar. 2023 was 24.89%.


Biogen EBITDA Margin % Historical Data

The historical data trend for Biogen's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.90 54.27 42.66 26.23 42.83

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBITDA Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.98 56.78 61.86 32.77 24.89

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen EBITDA Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Biogen's EBITDA Margin % falls in comparison to its industry or sector. The grey bar indicates the EBITDA Margin %'s extreme value range as defined by GuruFocus.



Biogen EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Biogen's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=730417.5/1705570.463
=42.83 %

Biogen's EBITDA Margin % for the quarter that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=121117.908/486565.661
=24.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BUE:BIIB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Biogen EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Biogen's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines